Trial results for a study investigating CT-based imaging parameters in Asthma patients were posted on ClinicalTrials.gov on 2025-11-18, revealing a significant association (p=0.007) from one linear regression analysis between imaging parameters and response to biologic therapies.
Background
Asthma is a chronic respiratory condition, and severe asthma can be particularly challenging to manage, often requiring advanced therapies such as biologics. However, not all patients respond uniformly to these treatments, leading to a need for better predictive tools. This study aimed to utilize CT-based imaging parameters of body composition to understand the heterogeneity of response to biologic therapies in severe asthma cohorts. By analyzing medical record data and CT images, researchers sought to derive imaging biomarkers that could predict therapeutic response, potentially guiding treatment decisions and improving patient outcomes.
Trial design
This completed study enrolled 233 participants with Asthma. The research involved forming a retrospective cohort of severe asthma patients on biologic therapies with computed tomography (CT) imaging and known outcomes on therapy, using University of Michigan EMR data. These images were analyzed using morphomics, a combination of high-throughput image analysis and deep learning techniques, to derive imaging biomarkers. These biomarkers were then tested in a second cohort from the National Jewish Health to assess for validity.
Key results
The study collected key measurements related to chest wall muscle size and quality from two cohorts. Mean values for Chest Wall Muscle Size included 95.49 cm2 (Standard Deviation: 25.63) and 87.98 cm2 (Standard Deviation: 23.65) from the University of Michigan cohort, and 97.82 cm2 (Standard Deviation: 29.04) and 102.86 cm2 (Standard Deviation: 28.77) from the National Jewish Health cohort. For Chest Wall Muscle Quality, mean values were 36.57 HU (Standard Deviation: 7.94) and 39.18 HU (Standard Deviation: 6.96) from the University of Michigan, and 30.27 HU (Standard Deviation: 7.28) and 28.60 HU (Standard Deviation: 6.43) from National Jewish Health. Additionally, measurements related to exacerbation reduction showed mean Chest Wall Muscle Size of 94.3 cm2 (Standard Deviation: 25.4) for the University of Michigan and 99.3 cm2 (Standard Deviation: 28.8) for National Jewish Health. Mean Chest Wall Muscle Quality for exacerbation reduction was 37 HU (Standard Deviation: 7.8) for the University of Michigan and 29.8 HU (Standard Deviation: 7) for National Jewish Health.
Linear regression analyses were performed, yielding the following p-values: 0.411, 0.161, 0.007, and 0.5. One analysis showed a statistically significant association with a p-value of 0.007.
What this means
The results suggest that CT-based imaging parameters of body composition may hold promise as biomarkers for predicting response to biologic therapies in severe asthma. The statistically significant p-value of 0.007 from one of the linear regression analyses indicates a notable association, implying that certain imaging characteristics could help clinicians identify which patients are more likely to benefit from specific biologic treatments. This could lead to more personalized treatment strategies for individuals with severe asthma, potentially reducing trial-and-error approaches and improving patient outcomes by tailoring therapy based on objective imaging biomarkers. Further research would be needed to validate these findings and integrate them into clinical practice.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT06922760, titled "Utilizing CT Based Imaging Parameters of Body Composition to Understand Heterogeneity of Response to Biologic Therapies in Severe Asthma Cohorts", were posted on 2025-11-18 on clinicaltrials.gov.